Metformin is one of the most widely prescribed medications in the world, and for good reason. Approved in the U.S. since 1994, it remains the recommended first-line treatment for type 2 diabetes, and its benefits extend beyond blood sugar control to include modest weight loss, improved cardiovascular outcomes, and potential advantages for conditions like polycystic ovary syndrome (PCOS). But whether metformin is “good for you” depends on why you’re taking it, how your body tolerates it, and how well your kidneys function.
What Metformin Actually Does in Your Body
Metformin’s primary job is lowering blood sugar, and it does this mainly by reducing the amount of glucose your liver releases into your bloodstream. Unlike some diabetes medications, it doesn’t force your pancreas to produce more insulin, which means the risk of dangerously low blood sugar is minimal.
At the cellular level, metformin concentrates inside your mitochondria (the energy-producing parts of your cells) at levels up to 1,000 times higher than outside the cell. There, it dials down energy production, which triggers a cellular energy sensor called AMPK. Once activated, AMPK flips a metabolic switch: it ramps up processes that burn fat and glucose for fuel while slowing down processes that store them. Over the long term, this improves how sensitive your liver and muscles are to insulin, which is the core problem in type 2 diabetes. There’s also growing evidence that metformin works partly through the gut, though that pathway is still being mapped out.
Proven Benefits for Diabetes
The American Diabetes Association recommends metformin as the preferred starting medication for adults and children over 10 with type 2 diabetes. If your hemoglobin A1C (a measure of average blood sugar over three months) is below 9% at diagnosis, metformin alone is typically enough. Above 9%, it’s usually combined with a second medication.
The cardiovascular benefits are significant. A large meta-analysis of 21 studies found that people with coronary artery disease who took metformin had a 33% lower risk of dying from any cause and a 19% lower risk of dying from heart-related events compared to those not taking it. Only two of the 21 studies showed any trend in the opposite direction. For a medication that costs pennies per pill, that’s a meaningful payoff.
Weight Loss: Real but Modest
Metformin does help with weight loss, though it’s not a dramatic effect. In people with diabetes, studies show losses ranging from about 2.7 kg (6 lbs) over four years to as much as 8 kg (17.6 lbs) over 24 weeks, depending on the study and starting weight. For comparison, other common diabetes drugs cause weight gain over the same periods.
In people without diabetes, the results are more modest. The large Diabetes Prevention Program trial found an average loss of 2.1 kg (about 4.6 lbs), though participants who stuck closely to their regimen lost about 3.5% of their body mass over two years. One smaller study of 31 non-diabetic obese individuals found an average loss of about 13 lbs over 28 weeks. Metformin is not a weight loss drug in the way newer GLP-1 medications are, but it nudges the scale in the right direction rather than the wrong one.
Benefits for PCOS
Metformin has become a common treatment for polycystic ovary syndrome, even though this use isn’t part of its original approval. PCOS involves insulin resistance, excess androgen hormones, and irregular ovulation, and metformin targets the root insulin problem. In women with PCOS, metformin reduces fasting insulin levels by roughly 40%, lowers circulating androgen levels, and helps restore regular menstrual cycles.
For fertility specifically, metformin can trigger ovulation on its own or alongside other fertility medications. Research consistently shows it helps restore menstrual regularity and improves ovulation rates, though it works best as part of a broader treatment plan rather than as a standalone fertility drug.
The Side Effects You Should Expect
Gut problems are the main downside. Up to 25% of people who start metformin experience nausea, diarrhea, or stomach pain, and about 5% find it intolerable enough to stop. These symptoms are linked to serotonin release in the intestine and tend to be worst in the first few weeks. Starting at a low dose and increasing gradually helps, and extended-release formulations are gentler on the stomach than immediate-release versions.
The more serious but rarer concern is lactic acidosis, a dangerous buildup of acid in the blood. This is almost exclusively a problem for people with reduced kidney function, which is why kidney testing is required before starting metformin. The current guidelines are clear: metformin is contraindicated if your eGFR (a measure of kidney filtration) falls below 30, and starting it isn’t recommended if your eGFR is between 30 and 45. If you’re already on metformin and your kidney function declines below 30, it should be stopped.
Vitamin B12 Depletion
One underappreciated risk is vitamin B12 deficiency. About 30% of long-term metformin users develop some degree of B12 malabsorption. B12 deficiency can cause fatigue, numbness and tingling in the hands and feet, and cognitive changes, symptoms that can easily be mistaken for diabetic nerve damage. If you’ve been on metformin for several years, periodic B12 testing is worth discussing.
The Anti-Aging Question
Metformin has attracted enormous attention as a potential anti-aging drug. Observational studies in people with diabetes have suggested protective effects against cardiovascular disease, certain cancers, and dementia. Meta-analyses have reported a 10% to 40% decrease in overall cancer incidence among metformin users with diabetes, though a rigorous 21-year randomized trial found no difference in cancer rates between metformin users and non-users among people at high risk for diabetes. The association seen in earlier studies may reflect metformin’s metabolic benefits rather than a direct anti-cancer effect.
The TAME (Targeting Aging with Metformin) trial is designed to answer the aging question more definitively. This U.S.-based study plans to enroll 3,000 adults aged 65 to 79 across roughly 14 centers and track a composite outcome of cardiovascular events, cancer, dementia, and death. Rather than studying metformin’s effect on each disease individually, TAME is testing whether it slows aging itself. If it succeeds, the implications would be enormous, but those results aren’t in yet. For now, the anti-aging potential of metformin is a reasonable hypothesis, not an established fact.
Who Benefits Most, and Who Should Avoid It
Metformin is clearly beneficial for people with type 2 diabetes. It lowers blood sugar without causing hypoglycemia, protects the heart, helps with weight, and costs very little. It’s also useful for women with PCOS who are dealing with insulin resistance, irregular cycles, or infertility.
People who should not take it include anyone with significantly reduced kidney function (eGFR below 30), active liver disease, or a history of lactic acidosis. Patients over 80 need kidney function testing before starting. It should also be temporarily stopped before certain imaging procedures that use contrast dye, particularly if kidney function is already borderline.
For healthy people without diabetes who are curious about metformin for weight loss or longevity, the evidence is thinner. The weight loss is modest, and the anti-aging data, while intriguing, comes mostly from observational studies in people who already had metabolic disease. The TAME trial may eventually change this picture, but right now, metformin’s strongest case is for the conditions it was designed to treat.